Gulam Abbas Manji MD PhD

Oncology•New York, NY

Gastrointestinal Cancer, Hematologic Oncology, Sarcoma

Assistant Professor

Request appointment

161 Fort Washington AvenueNew York, NY 10032
Book by Phone+1(802) 480-9693

Overview of Dr. Manji

Dr. Gulam Manji is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Ross University School of Medicine and has been in practice 17 years. He is one of 403 doctors at New York-Presbyterian Hospital and one of 127 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 50 publications and over 500 citings.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
Albany Med Health SystemResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2012 - 2027
OH State Medical License 2024 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2016-2017

Clinical Trials

PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2015 Nov 04
TERMINATED
PHASE1, PHASE2
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Start of enrollment: 2019 Nov 01
Terminated
Phase 2

Publications & Presentations

PubMed

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, Mitesh J Borad, Filippo Pietrantonio
The New England Journal of Medicine. 2026-07-23
EUS-guided drainage of symptomatic postoperative fluid collections: a retrospective cohort study evaluating timing of intervention and clinical outcomes.
Muhammad H Raza, Jonathan R Tiao, Catherine K Wang, Lyndon Luk, John B Doyle
Surgical Endoscopy. 2026-07-01
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.
Brian W Labadie, Aleksandar Obradovic, Alexander G Raufi, Urszula N Wasko, Lorenzo Tomassoni
JCO Precision Oncology. 2026-06-01

Lectures

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral ...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

US Cancer Clinics Scramble to Get Experimental Revolution Medicines Pancreatic Cancer DrugMay 14th, 2026
A Rare Story of Hope in Pancreatic Cancer TreatmentJanuary 9th, 2024
Researchers Discover How Pancreatic Cancer Cells Evade StarvationNovember 3rd, 2020

Grant Support

Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
Elucidation and targeting of paracrine cascades in PDACCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027